The U.S. Food and Drug Administration (FDA) has accepted Replimune's BLA resubmission for RP1 in combination with nivolumab, which targets advanced melanoma in patients who have not responded to prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback